Coordination of hydroxyquinolines to a ruthenium bis-dimethyl-phenanthroline scaffold radically improves potency for potential as antineoplastic agents

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8936-8946

  Heidary, David K ^a   Howerton, Brock S ^a   Glazer, Edith C ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; QUINOLINOL DERIVATIVE; RUTHENIUM BIS DIMETHYL PHENANTHROLINE; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG; CLIOQUINOL; COORDINATION COMPOUND; COPPER; CUPRIC CHLORIDE; PROTEASOME INHIBITOR; QUINOLINE DERIVATIVE; RUTHENIUM;

ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; APOPTOSIS; DRUG EFFECTS; HL 60 CELL LINE; IC50; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CLIOQUINOL; COORDINATION COMPLEXES; COPPER; HL-60 CELLS; HUMANS; HYDROXYQUINOLINES; INHIBITORY CONCENTRATION 50; PROTEASOME INHIBITORS; QUINOLINES; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923832140     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501043s     Document Type: Article

References (42)

1. Matlack, K. E.; Tardiff, D. F.; Narayan, P.; Hamamichi, S.; Caldwell, K. A.; Caldwell, G. A.; Lindquist, S. Clioquinol promotes the degradation of metal-dependent amyloid-beta (Abeta) oligomers to restore endocytosis and ameliorate Abeta toxicity Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (11) 4013-4018
2. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.; Huang, X.; Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; Masters, C. L.; Bush, A. I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimers disease transgenic mice Neuron 2001, 30 (3) 665-676
3. Bareggi, S. R.; Cornelli, U. Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders CNS Neurosci. Ther. 2011, 18 (1) 41-46
4. Pierre, J. L.; Baret, P.; Serratrice, G. Hydroxyquinolines as iron chelators Curr. Med. Chem. 2003, 10 (12) 1077-1084
5. Ding, W. Q.; Liu, B.; Vaught, J. L.; Yamauchi, H.; Lind, S. E. Anticancer activity of the antibiotic clioquinol Cancer Res. 2005, 65 (8) 3389-3395
6. Perez-Bolivar, C.; Takizawa, S. Y.; Nishimura, G.; Montes, V. A.; Anzenbacher, P. High-Efficiency Tris(8-hydroxyquinoline)aluminum (Alq(3)) Complexes for Organic White-Light-Emitting Diodes and Solid-State Lighting Chem.-Eur. J. 2011, 17 (33) 9076-9082
7. Warren, J. T.; Chen, W.; Johnston, D. H.; Turro, C. Ground-state properties and excited-state reactivity of 8-quinolate complexes of ruthenium(II) Inorg. Chem. 1999, 38 (26) 6187-6192
8. Sears, R. B.; Joyce, L. E.; Turro, C. Electronic tuning of ruthenium complexes by 8-quinolate ligands Photochem. Photobiol. 2010, 86 (6) 1230-1236
9. Ding, W. Q.; Lind, S. E. Metal ionophores-an emerging class of anticancer drugs IUBMB Life 2009, 61 (11) 1013-1018
10. Tardito, S.; Barilli, A.; Bassanetti, I.; Tegoni, M.; Bussolati, O.; Franchi-Gazzola, R.; Mucchino, C.; Marchio, L. Copper-dependent cytotoxicity of 8-hydroxyquinoline derivatives correlates with their hydrophobicity and does not require caspase activation J. Med. Chem. 2012, 55 (23) 10448-10459
11. Zhai, S.; Yang, L.; Cui, Q. C.; Sun, Y.; Dou, Q. P.; Yan, B. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells J. Biol. Inorg. Chem. 2010, 15 (2) 259-269
12. Hopkinson, R. J.; Tumber, A.; Yapp, C.; Chowdhury, R.; Aik, W.; Che, K. H.; Li, X. S.; Kristensen, J. B. L.; King, O. N. F.; Chan, M. C.; Yeoh, K. K.; Choi, H.; Walport, L. J.; Thinnes, C. C.; Bush, J. T.; Lejeune, C.; Rydzik, A. M.; Rose, N. R.; Bagg, E. A.; McDonough, M. A.; Krojer, T. J.; Yue, W. W.; Ng, S. S.; Olsen, L.; Brennan, P. E.; Oppermann, U.; Muller, S.; Klose, R. J.; Ratcliffe, P. J.; Schofield, C. J.; Kawamura, A. 5-Carboxy-8-hydroxyquinoline is a broad spectrum 2-oxoglutarate oxygenase inhibitor which causes iron translocation Chem. Sci. 2013, 4 (8) 3110-3117
13. Jacobsen, J. A.; Fullagar, J. L.; Miller, M. T.; Cohen, S. M. Identifying chelators for metalloprotein inhibitors using a fragment-based approach J. Med. Chem. 2011, 54 (2) 591-602
14. Dickens, M. G.; Franz, K. J. A prochelator activated by hydrogen peroxide prevents metal-induced amyloid Beta aggregation ChemBioChem 2010, 11 (1) 59-62
15. Perez, L. R.; Franz, K. J. Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease Dalton Trans 2010, 39 (9) 2177-2187
16. Howerton, B. S.; Heidary, D. K.; Glazer, E. C. Strained ruthenium complexes are potent light-activated anticancer agents J. Am. Chem. Soc. 2012, 134 (20) 8324-8327
17. Wachter, E.; Heidary, D. K.; Howerton, B. S.; Parkin, S.; Glazer, E. C. Light-activated ruthenium complexes photobind DNA and are cytotoxic in the photodynamic therapy window Chem. Commun. 2012, 48 (77) 9649-9651
18. Zeglis, B. M.; Pierre, V. C.; Barton, J. K. Metallo-intercalators and metallo-insertors Chem. Commun. (Cambridge, UK) 2007, 44, 4565-4579
19. Friedrich, J.; Seidel, C.; Ebner, R.; Kunz-Schughart, L. A. Spheroid-based drug screen: considerations and practical approach Nature Protoc. 2009, 4 (3) 309-324
20. Kunz-Schughart, L. A.; Freyer, J. P.; Hofstaedter, F.; Ebner, R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model J. Biomol. Screening 2004, 9 (4) 273-285
21. Herrmann, R.; Fayad, W.; Schwarz, S.; Berndtsson, M.; Linder, S. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids J. Biomol. Screening 2008, 13 (1) 1-8
22. Adams, J.; Palombella, V. J.; Sausville, E. A.; Johnson, J.; Destree, A.; Lazarus, D. D.; Maas, J.; Pien, C. S.; Prakash, S.; Elliott, P. J. Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 1999, 59 (11) 2615-2622
23. Goldberg, A. L. Development of proteasome inhibitors as research tools and cancer drugs J. Cell Biol. 2012, 199 (4) 583-588
24. Rock, K. L.; Goldberg, A. L. Degradation of cell proteins and the generation of MHC class I-presented peptides Annu. Rev. Immunol. 1999, 17, 739-779
25. Rock, K. L.; Gramm, C.; Rothstein, L.; Clark, K.; Stein, R.; Dick, L.; Hwang, D.; Goldberg, A. L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules Cell 1994, 78 (5) 761-771
26. Daniel, K. G.; Gupta, P.; Harbach, R. H.; Guida, W. C.; Dou, Q. P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells Biochem. Pharmacol. 2004, 67 (6) 1139-1151
27. Mao, X.; Li, X.; Sprangers, R.; Wang, X.; Venugopal, A.; Wood, T.; Zhang, Y.; Kuntz, D. A.; Coe, E.; Trudel, S.; Rose, D.; Batey, R. A.; Kay, L. E.; Schimmer, A. D. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma Leukemia 2009, 23 (3) 585-590
28. Schimmer, A. D. Clioquinol-a novel copper-dependent and independent proteasome inhibitor Curr. Cancer Drug Targets 2011, 11 (3) 325-331
29. Fuertes, M. A.; Alonso, C.; Perez, J. M. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance Chem. Rev. 2003, 103 (3) 645-662
30. Daniel, K. G.; Chen, D.; Orlu, S.; Cui, Q. C.; Miller, F. R.; Dou, Q. P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells Breast Cancer Res. 2005, 7 (6) R897-R908
31. Chen, D.; Cui, Q. C.; Yang, H.; Barrea, R. A.; Sarkar, F. H.; Sheng, S.; Yan, B.; Reddy, G. P.; Dou, Q. P. Clioquinol, a therapeutic agent for Alzheimers disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts Cancer Res. 2007, 67 (4) 1636-1644
32. Petrocca, F.; Altschuler, G.; Tan, S. M.; Mendillo, M. L.; Yan, H.; Jerry, D. J.; Kung, A. L.; Hide, W.; Ince, T. A.; Lieberman, J. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells Cancer Cell 2013, 24 (2) 182-196
33. Chen, Z. F.; Wei, J. H.; Liu, Y. C.; Liu, M.; Gu, Y. Q.; Huang, K. B.; Wang, M.; Liang, H. High antitumor activity of 5,7-dihalo-8-quinolinolato cerium complexes Eur. J. Med. Chem. 2013, 68, 454-462
34. Chen, Z. F.; Gu, Y. Q.; Song, X. Y.; Liu, Y. C.; Peng, Y.; Liang, H. Synthesis, crystal structure, cytotoxicity and DNA interaction of 5,7-dichloro-8-quinolinolato-lanthanides Eur. J. Med. Chem. 2013, 59, 194-202
35. Heidary, D. K.; Glazer, E. C. A light-activated metal complex targets both DNA and RNA in a fluorescent in vitro transcription and translation assay ChemBioChem 2014, 15 (4) 507-511
36. While it has been reported that 8-hydroxyquinoline inhibited RNA synthesis, this occurred at mM concentrations, well above the concentration used in our assay. See Fraser, R. S.; Creanor, J. The mechanism of inhibition of ribonucleic acid synthesis by 8-hydroxyquinoline and the antibiotic lomofungin Biochem. J. 1975, 147 (3) 401-410
37. Gobec, M.; Kljun, J.; Sosic, I.; Mlinaric-Rascan, I.; Ursic, M.; Gobec, S.; Turel, I. Structural characterization and biological evaluation of a clioquinol-ruthenium complex with copper-independent antileukaemic activity Dalton Trans 2014, 43 (24) 9045-9051
38. Barilli, A.; Atzeri, C.; Bassanetti, I.; Ingoglia, F.; DallAsta, V.; Bussolati, O.; Maffini, M.; Mucchino, C.; Marchio, L. Oxidative stress induced by copper and iron complexes with 8-hydroxyquinoline derivatives causes paraptotic death of HeLa cancer cells Mol. Pharmaceutics 2014, 11, 1151-1163
39. Martin Santos, C.; Cabrera, S.; Rios-Luci, C.; Padron, J. M.; Lopez Solera, I.; Quiroga, A. G.; Medrano, M. A.; Navarro-Ranninger, C.; Aleman, J. Novel clioquinol and its analogous platinum complexes: importance, role of the halogen substitution and the hydroxyl group of the ligand Dalton Trans 2013, 42 (37) 13343-13348
40. Yang, L.; Zhang, J.; Wang, C.; Qin, X.; Yu, Q.; Zhou, Y.; Liu, J. Interaction between 8-hydroxyquinoline ruthenium(II) complexes and basic fibroblast growth factors (bFGF): inhibiting angiogenesis and tumor growth through ERK and AKT signaling pathways Metallomics 2014, 6 (3) 518-531
41. Kljun, J.; Bratsos, I.; Alessio, E.; Psomas, G.; Repnik, U.; Butinar, M.; Turk, B.; Turel, I. New uses for old drugs: attempts to convert quinolone antibacterials into potential anticancer agents containing ruthenium Inorg. Chem. 2013, 52 (15) 9039-9052
42. Aguirre, J. D.; Angeles-Boza, A. M.; Chouai, A.; Turro, C.; Pellois, J. P.; Dunbar, K. R. Anticancer activity of heteroleptic diimine complexes of dirhodium: a study of intercalating properties, hydrophobicity and in cellulo activity Dalton Trans 2009, 48) 10806-10812